Abstract
Background
Most of the currently used antidepressant drugs are monoamine-based compounds, acting by the inhibition of re-uptake or metabolism of noradrenaline (NA) and/or serotonin (5-HT), because these neurotransmitters play a key role in the pathophysiology of depression. The aim of this study was to investigate the potential antidepressant-like activity of an endogenous amine, 1,2,3,4-tetrahydroisoquinoline (TIQ) and its close derivative, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ).
Methods
The experiments were carried out on male C57BL6J mice. The antidepressant-like activity of TIQs was evaluated in the behavioral tests: the forced swim test (FST) and tail suspension test (TST) and neurochemical analysis. TIQ and 1MeTIQ were administrated in three differences doses of 10, 25 or 50 mg/kg. Imipramine (IMI; 15 or 30 mg/kg) was used as a reference drug. In the neurochemical ex vivo study, the levels of NA, 5-HT and their metabolites, the rate of monoamine metabolism and their neuronal activity in different mouse brain structures were determined by HPLC with electrochemical detection.
Results
The results of this study have demonstrated that TIQ and 1MeTIQ produced antidepressant-like effect in the FST and TST because they significantly decreased the immobility time comparably to IMI. Biochemical data have demonstrated that administration of TIQs led to the activation of NA and 5-HT systems.
Conclusions
The results reported in this paper indicate that TIQ and 1MeTIQ possess a distinct antidepressant activity. In the light of these findings, we suggest that both tested compounds may be effective for the depression therapy in a clinical setting with better tolerance of side effects.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cantello R, Aguggia M, Gilli M, Delsedime M, Cutin IC, Riccio A, et al. Major depression in Parkinson’s disease and the mood response to intravenous methylphenidate: possible role of the hedonic dopamine synapse. J Neurol Neurosurg Psychiatry 1989;52:724–31.
Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of Alzheimer type and in Parkinson’s disease with and without dementia and depression. J Comp Neurol 1989;287:373–92.
Colpaert FC. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rats. Neuropharmacology 1987;26:1431–40.
Antkiewicz-Michaluk L. Action of antidepressant neuroleptics chlorprothixene and levomepromazine of the central noradrenergic system comparison with other antidepressants. Pol J Pharmacol Pharm 1985;37:667–77.
Maj J, Przegaliński E, Mogilnicka E. Hypotheses concerning the mechanism of action of antidepressant drugs. Rev Physiol Biochem Pharmacol 1984;100:1–74.
Sulser F. New perspectives on the molecular pharmacology of affective disorders. Eur Arch Psych Neurol 1989;238:231–9.
Richelson E. Pharmacology of antidepressants -characteristics of the ideal drug. Mayo Clinic Proc 1994;69:1069–81.
Vetulani J, Nalepa I. Antidepressants: past, present and future. Eur J Pharmacol 2000;405:351–63.
Bourin M. Is it possible to predict the activity of a new antidepressant in animals with simple psychopharmacological test. Fund Clin Pharmacol 1990;4:49–64.
Antkiewicz-Michaluk L, Michaluk J, Romańska I, Vetulani J. Effect of repetitive electroconvulsive treatment on sensitivity to pain and on [3H]-nitrendipine binding sites in cortical and hippocampal membranes. Psychopharmacology 1990;101:240–3.
Antkiewicz-Michaluk L, Romanska I, Michaluk J, Vetulani J. Role of calcium channels in effects of antidepressant drugs on responsiveness to pain. Psychopharmacology 1991;105:269–74.
Maj J, Górka Z, Melzacka M, Rawłów A, Pilc A. Chronic treatment with imipramine: further functional evidence for the enhanced noradrenaline transmission in flexor reflex activity. Naunyn-Schmied Arch Pharmacol 1983;322:256–60.
Sulser F. The role of CREB and other transcription factors in the pharmacotherapy and etiology of depression. Ann Med 2002;34:348–56.
Rommelspacher H, Susilo R. Tetrahydroisoquinolines and beta-carbolines: putative natural substances in plants and mammals. Prog Drug Res 1985;29:415–59.
Makino Y, Ohta S, Tachikawa O, Hirobe M. Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in foods: compounds related to Parkinson’s disease. Life Sci 1988;43:373–8.
Niwa T, Yoshizumi H, Tatematsu A, Matsuura S, Nagatsu T. Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. J Chromatogr 1989;493:347–52.
McNaught KS, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, et al. Isoquinoline derivatives as endogenous neurotoxins in the etiology of Parkinson’s disease. Biochem Pharmacol 1998;56:921–33.
Yamakawa T, Kotake Y, Fujitani M, Shintani H, Makino Y, Ohta S. Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Neurosci Lett 1999;276:67–70.
Nagatsu T. Isoquinoline neurotoxins in the brain and Parkinson’s disease. Neurosci Res 1997;29:99–111.
Naoi M, Matsuura S, Parvez H, Takahashi T, Hirata Y, Minami M, et al. Oxidation of N-methyl-1,2,3,4-tetrahydroisoquinoline into the N-methyl-isoquinolinium ion by monoamine oxidase. J Neurochem 1989;52:653–5.
Yamakawa T, Ohta S. Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction. Neurosci Lett 1999;259:157–60.
Yamakawa T, Ohta S. Isolation of 1-methyl-1,2,3,4-tetrahydroisoquinoline-synthesining enzyme from rat brain: a possible Parkinson’s disease-preventing enzyme. Biochem Biophys Res Commun 1997;236:676–81.
Naoi M, Maruyama W, Nagy GM. Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains. Neurotoxicology 2004;25:193–204.
Lorenc-Koci E, Wójcikowski J, Kot M, Haduch A. Disposition of 1,2,3,4-tetrahydroisoquinoline in the brain of male Wistar and Dark Agouti rats. Brain Res 2004;996:168–79.
Lorenc-Koci E, Antkiewicz-Michaluk L, Wardas J, Zapała M. Effect of 1,2,3,4-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase proteinand the binding of [3H]GBR12,935 to dopamine transporter in the rat nigrostriatal, dopaminergic system. Brain Res 2004;1009:67–81.
Antkiewicz-Michaluk L, Karolewicz B, Romańska I, Michaluk J, Bojarski A, Vetulani J. 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol 2003;466:263–9.
Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romanska I, Bojarski A, Vetulani J. Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol 2004;7:155–63.
Lorenc-Koci E, Sokołowska M, Kwiecień I, Włodek L. Treatment with 1,2,3,4-tetrahydroisoquinoline affects the levels of nitric oxide, S-nitrosothiols, glutathione and the enzymatic activity of gamma-glutamyl transpeptidase in the dopaminergic structures of rat brain. Brain Res 2005;1049:133–46.
Antkiewicz-Michaluk L, Łazarewicz JW, Patsenka A, Kajta M, Ziemińska E, Salińska E, et al. The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J Neurochem 2006;97:846–56.
Antkiewicz-Michaluk L, Michaluk J, Mokrosz M, Romanska I, Lorenc-Koci E, Ohta S, et al. Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. J Neurochem 2001;78:100–8.
Antkiewicz-Michaluk L, Filip M, Michaluk J, Romańska I. An endogenous neuroprotectant substance, 1-methyl- 1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats. J Neural Transm 2007;114:307–17.
Maruyama W, Nakahara D, Dostert P, Takahashi A. Naturally-occuring isoquinolines perturb monoamine metabolism in the brain: studied by in vivo microdialysis. J Neural Transm Gen Sect 1993;94:91–102.
Lorenc-Koci E, Śmiałowska M, Antkiewicz-Michaluk L, Gołembiowska K, Bajkowska M, Wolfarth S. Effect of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra, in rats. Neuroscience 2000;95:1049–59.
Patsenka A, Antkiewicz-Michaluk L. Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds -1,2,3,4-tetrahydroisoquinoline alkaloids. Pol J Pharmacol 2004;56:727–34.
Możdżeń E, Papp M, Gruca P, Wąsik A, Romańska I, Michaluk J, et al. 1,2,3,4-Tetrahydroisoquinoline produces an antidepressant-like effect in the forced swim test and chronic mild stress model of depression in the rat: neurochemical correlates. Eur J Pharmacol 2014;729:107–15.
Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978;47:379–91.
Kitamura Y, Kitagawa K, Kimoto S, Sagara H, Shibata K, Kawasaki H, et al. Selegilin exerts antidepressant-like effects during the forced swim test in adrenocorticotropic hormone-treated rats. J Pharmacol Sci 2008;106:639–44.
Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327–36.
Zomkowski AD, Santos AR, Rodrigues AL. Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett 2005;381:279–83.
Zhou D, Jin H, Lin HB, Yang X-M, Cheng YF, Deng FJ, et al. Antidepressant effect of the extracts from Fructus Akebiae. Pharmacol Biochem Behav 2010;94:488–95.
Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985;85:367–70.
Wang YM, Kong LD, Chen YM. Behavioural and biochemical effects of fractions prepared from Banxia Houpudecoction in depression models in mice. Phytother Res 2005;19:526–9.
Javaid JI, Perel JM, Davis JM. Inhibition of biogenic amines uptake by imipramine, desipramine, 2 OH-imipramine and 2 OH-desipramine in rat brain. Life Sci 1979;24:21–8.
Deakin JF. Depression and 5-HT. Int Clin Psychopharmacol 1991;6:23–8.
Borsini F. Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rev 1995;19:377–95.
Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995;121:66–72.
Lenders JWM, Eisenhofer G, Abeling NGGM, Berger W, Murphy DL, Konings H, et al. Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J Clin Invest 1996;97:1010–9.
Redrobe JP, Bourin M. Partial role of 5-HT3, and 5-HT2, receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 1997;325:129–35.
Danysz W, Kostowski W, Kozak W, Hauptmann M. On the role of noradrenergic neurotransmission in the action of desipramine and amitryptyline in animal models of depression. Pol J Pharmacol Pharm 1986;38:285–98.
Kitada Y, Miyauchi T, Kanazawa Y, Nakamichi H, Satoh S. Involvement of α -and β1-adrenergic mechanisms in the immobility-reducing action of desipramine in the forced swimming test. Neuropharmacology 1983;22:1055–60.
Dziedzicka-Wasylewska M, Faron-Górecka A, Rogoz Z, Solich J. The effect of combined treatment with imipramine and amantadine on the behavioral reactivity of central α1-adrenergic system in rats. Behav Pharmacol 2004;15:159–65.
Malinge M, Bourin M, Colombel MC, Larousse C. Additive effects of clonidine and antidepressant drugs in the mouse forced-swimming test. Psychopharmacology 1988;96:104–9.
O’Neill MF, Osborne DJ, Woodhouse SM, Conway MW. Selective imidazoline I2 ligands do not show antidepressant-like activity in the forced swim test in mice. J Psychopharmacol 2001;15:18–22.
Grunewald GL, Reitz TJ, Ruth JA, Vollmer S, Eiden LE, Rutledge CO. Inhibition of neuronal uptake of 3H-biogenic amines into rat cerebral cortex by partially and fully saturated derivatives of imipramine and desipramine. The importance of the aromatic ring in adrenergic amines -part 3. Biochem Pharmacol 1979;28:417–21.
Patsenka A, Michaluk J, Antkiewicz-Michaluk L. Tetrahydroisoquinoline alkaloids as endogenous inhibitors of brain monoamine oxidase, tyrosine hydroxylase and uptake of monoamines: in vitro study. 13th International Symposium on Molecular and Physiological Aspects of Regulatory Processes of the Organism. p. 344 Abstracts.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Możdżeń, E., Wąsik, A., Romańska, I. et al. Antidepressant-like effect of 1,2,3,4-tetrahydroisoquinoline and its methyl derivative in animal models of depression. Pharmacol. Rep 69, 566–574 (2017). https://doi.org/10.1016/j.pharep.2017.01.032
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2017.01.032